abbott diabetics

Quote

anonymous said:
ALERT: Donegal manufacturing expansion stalled for Libre 3; product quality issues, much lower than anticipated demand for Libre 3. 2021-2022 are shaping up to be a terrible year for ADC revenues. The massive depreciation expense (from the $2.3B 2018 - 2020 investements in Donegal, Witney, Flex Buffalo Grove, & Flex Austin) , is hitting Operating Margins heavily. Layoffs coming for ADC operations & quality.
Click to expand...

Damn more layoffs? ADC has put reps thru the ringer.
 








anonymous said:
ALERT: Donegal manufacturing expansion stalled for Libre 3; product quality issues, much lower than anticipated demand for Libre 3. 2021-2022 are shaping up to be a terrible year for ADC revenues. The massive depreciation expense (from the $2.3B 2018 - 2020 investements in Donegal, Witney, Flex Buffalo Grove, & Flex Austin) , is hitting Operating Margins heavily. Layoffs coming for ADC operations & quality.
Click to expand...

Last year Abbott made a big deal about Libre 3 CE mark and the roll out was Q1 of 2021. So maybe these issues are why there was only a limited product release in Germany. Libre 1 was similar....took some time to get it right.
 
















anonymous said:
ALERT: Donegal manufacturing expansion stalled for Libre 3; product quality issues, much lower than anticipated demand for Libre 3. 2021-2022 are shaping up to be a terrible year for ADC revenues. The massive depreciation expense (from the $2.3B 2018 - 2020 investements in Donegal, Witney, Flex Buffalo Grove, & Flex Austin) , is hitting Operating Margins heavily. Layoffs coming for ADC operations & quality.
Click to expand...

2021 revenue guidance for ADC & Abbott overall are going down - stock is dropping and stock price target is lowered (high $80s by 1Q 2022). Libre is becoming a commodity product and Abbott has to now absorb years of significant depreciation expense (~$650MM/year) from ADC's wild spending spree the last 2-3 years on Libre expansion.

No choice but to cut headcount across ADC and Abbott: areas targeted are Operations & Quality (Alameda, Witney, Donegal).
 








anonymous said:
2021 revenue guidance for ADC & Abbott overall are going down - stock is dropping and stock price target is lowered (high $80s by 1Q 2022). Libre is becoming a commodity product and Abbott has to now absorb years of significant depreciation expense (~$650MM/year) from ADC's wild spending spree the last 2-3 years on Libre expansion.

No choice but to cut headcount across ADC and Abbott: areas targeted are Operations & Quality (Alameda, Witney, Donegal).
Click to expand...

Way too many DVPs, Sr Directors, Directors across Abbott in Ops & QA anyway - will be good blodd-letting to lean down team to more doers and fewer execs
 








anonymous said:
Senseonics has great 180 day cgm data. Libre 3 doesn’t matter. Now go guide down earning again.
Click to expand...

Patients don't like to be cut. Very true in poorer countries. Plus the cost of the Doctor visits and surgery issues. Libre 3 and DexCom G7 will dominate the CGM market for a long time. Also, given that these devices are BLE, they can be used in a clinical environment for temporary glucose monitoring. Just need to have a PC or BLE enabled hospital monitor.
 
















anonymous said:
Patients don't like to be cut. Very true in poorer countries. Plus the cost of the Doctor visits and surgery issues. Libre 3 and DexCom G7 will dominate the CGM market for a long time. Also, given that these devices are BLE, they can be used in a clinical environment for temporary glucose monitoring. Just need to have a PC or BLE enabled hospital monitor.
Click to expand...

Dexcom's G7 is delayed by 2 years - it is not working, leaking moisture, and they can't get the design right. Even when it does come out at scale (4Q 2023) it is still larger than Libre 2 and unwieldy. G7 is no threat to ADC.
 
































anonymous said:
Dexcom's G7 is delayed by 2 years - it is not working, leaking moisture, and they can't get the design right. Even when it does come out at scale (4Q 2023) it is still larger than Libre 2 and unwieldy. G7 is no threat to ADC.
Click to expand...

Really? ADC has a sensor that is better suited for a small on body piece. I know that DexCom partnered with Google back in 2015 to do the G7 in order to compete with Libre. In a way they had to start from scratch...new sensor, new inserter, and new electronics. Whereas ADC has been using their sensor for years and have a lot of experience with it. In the quarterly meetings DexCom has been a bit evasive about the G7 status. Wonder how Libre 3 is doing? It's shipping in Germany.
 








anonymous said:
Really? ADC has a sensor that is better suited for a small on body piece. I know that DexCom partnered with Google back in 2015 to do the G7 in order to compete with Libre. In a way they had to start from scratch...new sensor, new inserter, and new electronics. Whereas ADC has been using their sensor for years and have a lot of experience with it. In the quarterly meetings DexCom has been a bit evasive about the G7 status. Wonder how Libre 3 is doing? It's shipping in Germany.
Click to expand...

Dexcom G7 partnering with both Lilly and Novo.also It will be good that they combined both sensors. Easy to insert. Especially for seniors. Also the Libre doesn’t have alerts. Which is why I am going back to Dexcom once G7 hits.
 
























anonymous said:
Dexcom G7 partnering with both Lilly and Novo.also It will be good that they combined both sensors. Easy to insert. Especially for seniors. Also the Libre doesn’t have alerts. Which is why I am going back to Dexcom once G7 hits.
Click to expand...

Actually Libre 3 does have alerts. Given that Libre 3 already has CE it's almost certain that it will get FDA prior to G7.
 








anonymous said:
Dexcom's G7 is delayed by 2 years - it is not working, leaking moisture, and they can't get the design right. Even when it does come out at scale (4Q 2023) it is still larger than Libre 2 and unwieldy. G7 is no threat to ADC.
Click to expand...

I was looking for some info on Libre 3:

www.abbott.com/corpnewsroom/diabetes-care/how-good-is-FreeStyle-Libre-3-they-are-here-to-testify.html

Above is a bit of ADC propaganda but, given that Libre 3 is in Germany, one can find reviews on the Libre 3. Abbott was very quite about this product after the CE mark in Sept 2020. Now they are talking about it. I think Abbott was being careful about the roll out so as to avoid the quality issues experienced with Libre 1. That is work out the bugs prior to a full EU release. The point is the product is in production and on the market, has EU approval, and FDA submission, so it is at least a year ahead of G7. Not vaporware.
 
















anonymous said:
G7 will still have the advantage with combined sensors and easy to insert not to mention partnering with the big boys at Novo and Lilly.!
Click to expand...

The G7 sensor is not that much smaller than the Libre 2 and a lot bigger than the Libre 3. Check out the video on the Libre 3 sensor insertion. Very simple and is combined. The G7 is better than Libre 2 but is not as good as Libre 3.
 
















Top Bottom
Back
Quote